Sam Friedman
Research Subjects
Sam Friedman has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Josh Spurrier
Department of Neurology, Yale University School of Medicine, New Haven, CT, USA
49 shared publications - Juan C. Vasquez
Department of Pediatrics, Yale School of Medicine, New Haven, Connecticut
49 shared publications - Karlie N. Lucas
Department of Therapeutic Radiology, Yale University, New Haven, CT, USA
49 shared publications - Katelyn J. Noronha
Department of Molecular Biophysics and Biochemistry, Yale School of Medicine, New Haven, Connecticut
49 shared publications - Ranjini K. Sundaram
Department of Therapeutic Radiology, Yale School of Medicine, New Haven, Connecticut
49 shared publications - Brian Shuch
UCLA School of Medicine 14 Institute of Urologic Oncology Los Angeles, California
40 shared publications
Latest Publications
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from NAPRT Expression and Epigenetic Regulation in Pediatric Rhabdomyosarcoma as a Potential Biomarker for NAMPT Inhibition
NAPRT-deficient RMS models are sensitive to FK866 and cannot be rescued with NA
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from NAPRT Expression and Epigenetic Regulation in Pediatric Rhabdomyosarcoma as a Potential Biomarker for NAMPT Inhibition
NAPRT-deficient RMS models are sensitive to FK866 and cannot be rescued with NA
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from NAPRT Expression and Epigenetic Regulation in Pediatric Rhabdomyosarcoma as a Potential Biomarker for NAMPT Inhibition
Functional validation of single-cell clones of CRISPR/Cas9 ribonucleoprotein (RNP) based NAPRT knock-out model
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from NAPRT Expression and Epigenetic Regulation in Pediatric Rhabdomyosarcoma as a Potential Biomarker for NAMPT Inhibition
Functional validation of single-cell clones of CRISPR/Cas9 ribonucleoprotein (RNP) based NAPRT knock-out model
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from NAPRT Expression and Epigenetic Regulation in Pediatric Rhabdomyosarcoma as a Potential Biomarker for NAMPT Inhibition
Supplementary Figure 2. NAPRT-deficient RMS models are not able to utilize NA to rescue cell viability
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from NAPRT Expression and Epigenetic Regulation in Pediatric Rhabdomyosarcoma as a Potential Biomarker for NAMPT Inhibition
Supplementary Figure 2. NAPRT-deficient RMS models are not able to utilize NA to rescue cell viability
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from NAPRT Expression and Epigenetic Regulation in Pediatric Rhabdomyosarcoma as a Potential Biomarker for NAMPT Inhibition
Supplementary Figure 3. Generation of plasmid based NAPRT overexpressing isogenic model.
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from NAPRT Expression and Epigenetic Regulation in Pediatric Rhabdomyosarcoma as a Potential Biomarker for NAMPT Inhibition
Supplementary Figure 3. Generation of plasmid based NAPRT overexpressing isogenic model.
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from NAPRT Expression and Epigenetic Regulation in Pediatric Rhabdomyosarcoma as a Potential Biomarker for NAMPT Inhibition
Supplementary Figure 7. Clinical Correlates of NAPRT Expression in RMS patient samples.
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from NAPRT Expression and Epigenetic Regulation in Pediatric Rhabdomyosarcoma as a Potential Biomarker for NAMPT Inhibition
Supplementary Figure 7. Clinical Correlates of NAPRT Expression in RMS patient samples.
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Tables from NAPRT Expression and Epigenetic Regulation in Pediatric Rhabdomyosarcoma as a Potential Biomarker for NAMPT Inhibition
Supplementary Tables with list of antibodies and description of TMAs
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables from NAPRT Expression and Epigenetic Regulation in Pediatric Rhabdomyosarcoma as a Potential Biomarker for NAMPT Inhibition
Supplementary Tables with list of antibodies and description of TMAs
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from NAPRT Expression and Epigenetic Regulation in Pediatric Rhabdomyosarcoma as a Potential Biomarker for NAMPT Inhibition
Supplementary Figure 5. Induction of apoptosis in RMS models with OT-82 treatment
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from NAPRT Expression and Epigenetic Regulation in Pediatric Rhabdomyosarcoma as a Potential Biomarker for NAMPT Inhibition
Supplementary Figure 5. Induction of apoptosis in RMS models with OT-82 treatment
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from NAPRT Expression and Epigenetic Regulation in Pediatric Rhabdomyosarcoma as a Potential Biomarker for NAMPT Inhibition
Supplementary Figure 6. Tumor volumes in RMS isogenic models after OT-82 treatment.
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from NAPRT Expression and Epigenetic Regulation in Pediatric Rhabdomyosarcoma as a Potential Biomarker for NAMPT Inhibition
Supplementary Figure 6. Tumor volumes in RMS isogenic models after OT-82 treatment.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 8 from NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities via NAD+ Depletion
NAPRT silencing confers sensitivity to NAMPTis in IDH1/2 mutant cancer cell line models.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 8 from NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities via NAD+ Depletion
NAPRT silencing confers sensitivity to NAMPTis in IDH1/2 mutant cancer cell line models.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities via NAD+ Depletion
Results from GO Pathway Analysis in FH-deficient cell lines.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities via NAD+ Depletion
Results from GO Pathway Analysis in FH-deficient cell lines.